Could the inhibition of IL-17 or IL-18 be a potential therapeutic opportunity for gastric cancer?
- Author(s)
- Nguyen, PM; Putoczki, TL;
- Journal Title
- Cytokine
- Publication Type
- Journal Article in press
- Abstract
- Chronic inflammation is recognized as a key tumor-promoting factor in a number of epithelial cancers, including gastric cancer (GC). The production of pro-inflammatory cytokines in the tumor microenvironment by both the innate and the adaptive immune response can activate signaling pathways that are associated with increased cell survival and proliferation of cancer cells. Among the cytokines that have most commonly been linked to inflammation-associated cancers, are the Th17 cell-associated cytokines IL-17A, IL-23, IL-22, and the IL-1 family members IL-1beta and IL-18. However, whether their contribution to inflammation-associated cancers is universal, or specific to individual types of cancers, remains to be elucidated. This review will explore our current understanding of the known roles of these cytokines in gastritis and discuss how their therapeutic inhibition may be useful for GC.
- Publisher
- Elsevier
- Research Division(s)
- Inflammation
- PubMed ID
- 29396054
- Publisher's Version
- https://doi.org/10.1016/j.cyto.2018.01.008
- Open Access at Publisher's Site
https://doi.org/10.1016/j.cyto.2018.01.008- NHMRC Grants
- NHMRC/1080498, NHMRC/1098643,
- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2018-02-28 08:04:57
Last Modified: 2018-02-28 08:33:19